New drug VVZ-2471 gets first safety check in healthy volunteers
NCT ID NCT07531316
First seen Apr 20, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This early-stage trial will test the safety and tolerability of an experimental drug, VVZ-2471, in 60 healthy adults who show high impulsivity. Participants will take either the drug or a placebo twice daily for 14 days. The results will help researchers decide whether to study the drug further in people who use substances.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY CONTROLS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
VCU Institute for Drug and Alcohol Studies
Richmond, Virginia, 23219, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VVZ-2471
What this could lead to
If successful, this study could pave the way for future trials testing VVZ-2471 in people who use substances, potentially leading to new treatments for substance use disorders.
What could go wrong
This is an early Phase 1 safety study in healthy volunteers, not patients. The drug may prove unsafe or poorly tolerated, and even if safe here, it may not help with substance use in later trials.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.